echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > 2021 USPSTF Recommendations: Statement of Screening Recommendations for Hepatitis B Virus Infection in Adolescents and Adults

    2021 USPSTF Recommendations: Statement of Screening Recommendations for Hepatitis B Virus Infection in Adolescents and Adults

    • Last Update: 2021-02-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Hepatitis B virus (HBV), or HBV, is a DNA virus that causes the pathogen of hepatitis B.
    , HBV infection is a global public health problem, with the prevalence of hepatitis B vaccine increasing year by year, the infection rate is declining.
    , however, according to CDC data, about 68 percent of people with chronic hepatitis B are unaware of their infection, and many remain asymptomatic until the onset of cirrhosis or end-stage liver disease.
    , the U.S. Preventive Services Task Force (USPSTF) reviewed previous recommendations based on new randomized clinical trials and queue studies published between 2014 and August 2019 to assess the health outcomes of antiviral therapy, as well as the safety and accuracy of HBV's new screening strategies and screening tools for high-risk populations.
    Risk Assessment This update and expansion of previous screenings for HBV infection in high-risk populations, the USPSTF recommends screening for HBV infections in adolescents and adults at higher risk, including vaccinated populations.
    the U.S. Centers for Disease Control and Prevention and the American Association for the Study of Hepatology recommend screening for patients who require immunosuppressive treatment, predialysis, hemodialysis, peritiopathy, or home dialysis.
    same time, the USPSTF offered different views on screening pregnant women.
    of HBV infection in non-U.S.-born people living in the U.S. varies greatly from country of origin to country of origin.
    born in a country with a prevalence of 2% or more of HBsAg... MedSci Original Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mets Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
    all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
    at the same time reproduced content does not represent the position of this site.
    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.